188 related articles for article (PubMed ID: 34938663)
1. Clinical Features and Prognostic Risk Prediction of Non-Hodgkin Lymphoma-Associated Hemophagocytic Syndrome.
Yao S; Jin Z; He L; Zhang R; Liu M; Hua Z; Wang Z; Wang Y
Front Oncol; 2021; 11():788056. PubMed ID: 34938663
[TBL] [Abstract][Full Text] [Related]
2. [Clinical characteristics and prognosis of lymphoma-associated hemophagocytic syndrome].
Zhao AL; Li M; Li LF; Gan XA; Wang J; Li H; Shen K; Yang YF; Niu T
Zhonghua Yi Xue Za Zhi; 2022 Jul; 102(28):2173-2180. PubMed ID: 35872581
[No Abstract] [Full Text] [Related]
3. Multivariate analysis of prognosis for patients with natural killer/T cell lymphoma-associated hemophagocytic lymphohistiocytosis.
Jin Z; Wang Y; Wang J; Wu L; Pei R; Lai W; Wang Z
Hematology; 2018 May; 23(4):228-234. PubMed ID: 28982299
[TBL] [Abstract][Full Text] [Related]
4. Epstein-Barr Virus-Positive Lymphoma-Associated Hemophagocytic Syndrome: A Retrospective, Single-Center Study of 51 Patients.
Zhao A; Yang J; Li M; Li L; Gan X; Wang J; Li H; Shen K; Yang Y; Niu T
Front Immunol; 2022; 13():882589. PubMed ID: 35479073
[TBL] [Abstract][Full Text] [Related]
5. Lymphoma-associated hemophagocytic syndrome: a retrospective study from a single center.
Li N; Jiang M; Wu WC; Zhou HJ; Zou LQ
Hematology; 2022 Dec; 27(1):909-916. PubMed ID: 35993333
[TBL] [Abstract][Full Text] [Related]
6. Clinical features and treatment of natural killer/T cell lymphoma associated with hemophagocytic syndrome: comparison with other T cell lymphoma associated with hemophagocytic syndrome.
Han L; Li L; Wu J; Li X; Zhang L; Wang X; Fu X; Ma W; Sun Z; Zhang X; Chang Y; Guo S; Zhang M
Leuk Lymphoma; 2014 Sep; 55(9):2048-55. PubMed ID: 24359240
[TBL] [Abstract][Full Text] [Related]
7. Lymphoma associated hemophagocytic syndrome: A single-center retrospective study.
Chang Y; Cui M; Fu X; Han L; Zhang L; Li L; Li X; Sun Z; Wu J; Zhang X; Li Z; Nan F; Yan J; Sheng G; Zhang M
Oncol Lett; 2018 Jul; 16(1):1275-1284. PubMed ID: 30061947
[TBL] [Abstract][Full Text] [Related]
8. Clinical characteristics of extranodal NK/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis.
Liu YZ; Bi LQ; Chang GL; Guo Y; Sun S
Cancer Manag Res; 2019; 11():997-1002. PubMed ID: 30774427
[TBL] [Abstract][Full Text] [Related]
9. [Lymphoma-associated hemophagocytic syndrome in Japan].
Takahashi N; Chubachi A; Miura I; Nakamura S; Miura AB
Rinsho Ketsueki; 1999 Jul; 40(7):542-9. PubMed ID: 10483136
[TBL] [Abstract][Full Text] [Related]
10. Risk factor analysis of non-Hodgkin lymphoma-associated haemophagocytic syndromes: a multicentre study.
Sano H; Kobayashi R; Tanaka J; Hashino S; Ota S; Torimoto Y; Kakinoki Y; Yamamoto S; Kurosawa M; Hatakeyama N; Haseyama Y; Sakai H; Sato K; Fukuhara T
Br J Haematol; 2014 Jun; 165(6):786-92. PubMed ID: 24606577
[TBL] [Abstract][Full Text] [Related]
11. Clinical Efficacy of Programmed Cell Death Ligand 1 Antibody in Treatment of Extranodal Natural Killer/T-Cell Lymphoma With Hemophagocytic Lymphohistiocytosis.
Yang CL; Chen X; Zhou HJ; Wu WC; Zou LQ
J Hematol; 2024 Apr; 13(1-2):46-51. PubMed ID: 38644986
[TBL] [Abstract][Full Text] [Related]
12. Autologous Hematopoietic Stem Cell Transplantation for Patients with Lymphoma-Associated Hemophagocytic lymphohistiocytosis.
Song Y; Yin Q; Wang J; Wang Z
Cell Transplant; 2021; 30():9636897211057077. PubMed ID: 34743574
[TBL] [Abstract][Full Text] [Related]
13. The emerging role of anti-PD-1 antibody-based regimens in the treatment of extranodal NK/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis.
He Y; Gao Y; Ping L; He H; Huang C; Bai B; Wang X; Li Z; Cai Q; Huang Y; Pan X; Zeng W; Liu Y; Huang H
J Cancer Res Clin Oncol; 2023 May; 149(5):2017-2027. PubMed ID: 35809114
[TBL] [Abstract][Full Text] [Related]
14. Serum sCD25/ferritin ratio combined with MCP-1 is a valid predictor for identifying LAHS with HLH as the first manifestation.
Zou H; He L; Hue Z; Liu M; Yao S; Zhu Y; Wang Z; Wang Y
J Cancer Res Clin Oncol; 2023 Sep; 149(11):8521-8533. PubMed ID: 37093345
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of lymphocyte function by IFN-γ secretion capability assay in the diagnosis of lymphoma-associated hemophagocytic syndrome.
Hou H; Luo Y; Wang F; Yu J; Li D; Sun Z
Hum Immunol; 2019 Dec; 80(12):1006-1011. PubMed ID: 31540793
[TBL] [Abstract][Full Text] [Related]
16. [The diagnostic value of flow cytometry in patients with lymphoma associated hemophagocytic syndrome].
Zhang WL; Xu L; Zhang Q; Zhong FL; Dai J; Feng J; Sun LH; Xu HC; Xie WY; Zhang HY
Zhonghua Nei Ke Za Zhi; 2020 Dec; 59(12):976-981. PubMed ID: 33256339
[No Abstract] [Full Text] [Related]
17. An effective diagnostic index for lymphoma-associated hemophagocytic syndrome.
Xie M; Li L; Zhu L; Zhou D; Yang X; Sun J; Zhu J; Zhu M; Zheng Y; Xie W; Ye X
QJM; 2018 Aug; 111(8):541-547. PubMed ID: 29800321
[TBL] [Abstract][Full Text] [Related]
18. Identification of clinical features of lymphoma-associated hemophagocytic syndrome (LAHS): an analysis of 69 patients with hemophagocytic syndrome from a single-center in central region of China.
Li F; Li P; Zhang R; Yang G; Ji D; Huang X; Xu Q; Wei Y; Rao J; Huang R; Chen G
Med Oncol; 2014 Apr; 31(4):902. PubMed ID: 24610542
[TBL] [Abstract][Full Text] [Related]
19. How to Identify Patients at High Risk of Developing Nasal-Type, Extranodal Nature Killer/T-Cell Lymphoma-Associated Hemophagocytic Syndrome.
Li N; Jiang M; Wu WC; Wei WW; Zou LQ
Front Oncol; 2021; 11():704962. PubMed ID: 34490105
[TBL] [Abstract][Full Text] [Related]
20. High concentration of miR-133 is a useful marker for the diagnosis of lymphoma- associated hemophagocytic syndrome.
Li W; Zhong Y; Shuang Y; Huang H; Huang Y; Yu L; Huang X
Cancer Biomark; 2017 Aug; 20(2):159-164. PubMed ID: 28869447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
